Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tegavivint |
| Synonyms | |
| Therapy Description |
Tegavivint (BC2059) binds to beta-catenin (CTNNB1) and interferes with binding to TBL1 and TBLR1, resulting in increased degradation of beta-catenin and potentially leading to increased apoptosis of tumor cells with activated canonical Wnt signaling (PMID: 28500235, PMID: 30793158). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tegavivint | BC-2059|BC 2059|Tegatrabetan|BC2059 | CTNNB1 Inhibitor 27 | Tegavivint (BC2059) binds to beta-catenin (CTNNB1) and interferes with binding to TBL1 and TBLR1, resulting in increased degradation of beta-catenin and potentially leading to increased apoptosis of tumor cells with activated canonical Wnt signaling (PMID: 28500235, PMID: 30793158). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CTNNB1 act mut | hepatocellular carcinoma | predicted - sensitive | Tegavivint | Phase Ib/II | Actionable | In a Phase I/II trial, Tegavivint (BC2059) treatment was tolerated and demonstrated preliminary efficacy with 1 partial response (PR) and stable disease (SD) in 8 of 15 evaluable patients with advanced hepatocellular carcinoma, 6 of the 7 patients harboring CTNNB1 activation mutations achieved a best response of PR or SD, comparing to 3 in 8 of the CTNNB1 wild-type patients (Cancer Res (2025) 85 (8_Supplement_2): CT032; NCT05797805). | detail... |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03459469 | Phase I | Tegavivint | Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 | Completed | USA | CAN | 0 |
| NCT05755087 | Phase I | Tegavivint | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | Recruiting | USA | 0 |
| NCT04851119 | Phase Ib/II | Tegavivint | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |
| NCT05797805 | Phase Ib/II | Tegavivint Lenvatinib + Tegavivint Cabozantinib + Tegavivint | A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | Recruiting | USA | CAN | 0 |
CKB BOOST